SCHEMBL4444188

SCHEMBL4444188

O=C(O)NC1CCCN(c2ccncc2[N+](=O)[O-])C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.46
ALDH1A1 P00352 6/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 3/20 0.43
HTT P42858 3/20 0.43
LMNA P02545 3/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ROCK1 Q13464 2/20 0.41
CDC42BPB Q9Y5S2 2/20 0.41
TDP1 Q9NUW8 1/20 0.40
USP2 O75604 1/20 0.39
THRB P10828 1/20 0.39
S100A4 P26447 1/20 0.39
RECQL P46063 1/20 0.39
LCK P06239 1/20 0.39
JAK3 P52333 1/20 0.39
BTK Q06187 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15873245 1.00 MAPT (0.46) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL4443908 1.00 MAPT (0.46) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL15873243 1.00 MAPT (0.46) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL16505742 0.93 MEN1 (0.43) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL16505743 0.93 MEN1 (0.43) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL16504791 0.93 MEN1 (0.43) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL16515365 0.93 MEN1 (0.43) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL16504790 0.93 MEN1 (0.43) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL16505447 0.91 POLB (0.48) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL13736923 0.91 ALDH1A1 (0.46) MAPTALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 US disclosed
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors AMGEN INC. 2014-08-07 US disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
EP-2132177-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE Novartis Ag (CH) 2009-12-16 EP disclosed
WO-2008106692-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors PIM1, PIM2, PIM3 MAPT 3306/4885ALDH1A1 719/4885MEN1 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.